二氟甲基鸟氨酸：聚胺中的证据。
Difluoromethylornithine: the proof is in the polyamines.
机构信息
Department of Medicine, The University of Arizona Cancer Center, Tucson, Arizona 85719, USA.
出版信息
Cancer Prev Res (Phila). 2012 Dec;5(12):1341-4. doi: 10.1158/1940-6207.CAPR-12-0429.
Abstract
In this issue (beginning on page 1368), Kreul and colleagues report a retrospective review of long-term efficacy and toxicity for subjects participating in a phase III study of difluoromethylornithine (DFMO) for prevention of nonmelanoma skin cancer (NMSC). They conclude that those treated with DFMO had a nonsignificant, persistent decrease in NMSC after completion of treatment and that treatment with DFMO did not result in late toxicity after the discontinuation of treatment. We review the data on DFMO as a chemopreventive agent for skin and other cancers, discuss the necessary qualities of a cancer chemopreventive agent, and reflect on the requirements for a well-conducted cancer chemoprevention study, including the rationale for long-term follow-up in cancer prevention studies.
摘要
在本期（第 1368 页开始），Kreul 及其同事报告了一项参与 III 期研究的受试者的回顾性分析，该研究使用二氟甲基鸟氨酸（DFMO）预防非黑色素瘤皮肤癌（NMSC）。他们得出的结论是，DFMO 治疗组在治疗完成后 NMSC 持续且无显著性降低，并且在停止治疗后，DFMO 治疗不会导致迟发性毒性。我们回顾了 DFMO 作为皮肤和其他癌症化学预防剂的数据，讨论了癌症化学预防剂的必要特性，并思考了进行良好癌症化学预防研究的要求，包括癌症预防研究中进行长期随访的理由。
相似文献
1
Difluoromethylornithine: the proof is in the polyamines.
Cancer Prev Res (Phila). 2012 Dec;5(12):1341-4. doi: 10.1158/1940-6207.CAPR-12-0429.
2
A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.
Cancer Prev Res (Phila). 2012 Dec;5(12):1368-74. doi: 10.1158/1940-6207.CAPR-12-0233. Epub 2012 Oct 11.
3
Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):657-61.
4
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
Cancer Prev Res (Phila). 2010 Jan;3(1):35-47. doi: 10.1158/1940-6207.CAPR-09-0096.
5
Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Clin Cancer Res. 2002 Jan;8(1):149-55.
6
Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):907-12.
7
Chemopreventive effect of difluoromethylornithine (DFMO) on mouse skin squamous cell carcinomas induced by benzo(a)pyrene.
J Cell Biochem Suppl. 1997;28-29:81-9.
8
Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.
Cancer Prev Res (Phila). 2016 Feb;9(2):128-34. doi: 10.1158/1940-6207.CAPR-15-0232. Epub 2015 Dec 28.
9
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9. doi: 10.1158/1055-9965.EPI-07-0658.
10
Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
Laryngoscope. 2023 Mar;133(3):676-682. doi: 10.1002/lary.30231. Epub 2022 May 27.
引用本文的文献
1
Polyamine Derived Photosensitizer: A Novel Approach for Photodynamic Therapy of Cancer.
Molecules. 2024 Sep 9;29(17):4277. doi: 10.3390/molecules29174277.
2
Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.
Front Oncol. 2023 Nov 15;13:1281844. doi: 10.3389/fonc.2023.1281844. eCollection 2023.
3
Downregulation of MTAP promotes Tumor Growth and Metastasis by regulating ODC Activity in Breast Cancer.
Int J Biol Sci. 2022 Apr 24;18(7):3034-3047. doi: 10.7150/ijbs.67149. eCollection 2022.
4
Application of Hantzsch reaction for sensitive determination of eflornithine in cream, plasma and urine samples.
R Soc Open Sci. 2021 May 12;8(5):210366. doi: 10.1098/rsos.210366.
5
Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.
Med Sci (Basel). 2018 Feb 8;6(1):12. doi: 10.3390/medsci6010012.
6
Non-canonical Hedgehog/AMPK-Mediated Control of Polyamine Metabolism Supports Neuronal and Medulloblastoma Cell Growth.
Dev Cell. 2015 Oct 12;35(1):21-35. doi: 10.1016/j.devcel.2015.09.008.
7
Say what? The activity of the polyamine biosynthesis inhibitor difluoromethylornithine in chemoprevention is a result of reduced thymidine pools?
Cancer Discov. 2013 Sep;3(9):975-7. doi: 10.1158/2159-8290.CD-13-0427.
8
Cytotoxicity of 1,4-diamino-2-butanone, a putrescine analogue, to RKO cells: mechanism and redox imbalance.
Free Radic Res. 2013 Sep;47(9):672-82. doi: 10.3109/10715762.2013.814126. Epub 2013 Jul 8.
本文引用的文献
1
A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.
Cancer Prev Res (Phila). 2012 Dec;5(12):1368-74. doi: 10.1158/1940-6207.CAPR-12-0233. Epub 2012 Oct 11.
2
Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia.
Cancer Prev Res (Phila). 2011 Jun;4(6):829-39. doi: 10.1158/1940-6207.CAPR-10-0243.
3
Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry.
Anal Quant Cytol Histol. 2009 Dec;31(6):355-66.
4
Cancer statistics, 2010.
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
5
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
Cancer Prev Res (Phila). 2010 Jan;3(1):35-47. doi: 10.1158/1940-6207.CAPR-09-0096.
6
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
Cancer Prev Res (Phila). 2008 Jun;1(1):32-8. doi: 10.1158/1940-6207.CAPR-08-0042.
7
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9. doi: 10.1158/1055-9965.EPI-07-0658.
8
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
J Natl Cancer Inst. 2007 Feb 21;99(4):272-82. doi: 10.1093/jnci/djk049.
9
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
J Urol. 2006 Aug;176(2):500-4. doi: 10.1016/j.juro.2006.03.061.
10
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA. 2006 Jun 21;295(23):2727-41. doi: 10.1001/jama.295.23.joc60074. Epub 2006 Jun 5.
Zotero 插件